July 30, 2021 – Abbott (Abbott Park, IL) announced the U.S. launch of Jot Dx, the company’s latest insertable cardiac monitor (ICM). The Jot Dx ICM gives clinicians and hospitals control of how they manage the flow of information through a unique feature to view either all abnormal heart rhythm data or to simplify which irregular heart rhythms are recorded with a “key episodes” option.
This technology allows for remote detection and improved diagnosis accuracy of cardiac arrhythmia in patients. Jot Dx ICM is supported by SyncUP, a personalized service that delivers one-on-one training and education to help patients connect to their ICM.
Jot Dx ICM continuously monitors patient cardiac rhythms and connects directly to myMerlin, a mobile app that transmits data in real-time to both the clinician and patient. For the first time in an ICM, Jot provides clinicians increased control over patient monitoring, with an option to toggle between viewing only three key episodes or all episodes depending on individual patient needs to make and accurate diagnosis, the company says.
A key element in the setup of Jot Dx ICM and the myMerlin mobile app is the new SyncUP support service, which Abbott offers on select products as part of its connected care portfolio. With SyncUP, an Abbott support expert will enroll a patient with a newly implanted device in the system, orient them through getting to know their new heart monitoring device and confirm connection to the myMerlin app.
SyncUP also support patients with Abbott’s implantable defibrillator, Gallant ICD.